Prevention and reversal of hepatic steatosis with a high-protein diet in mice

Biochim Biophys Acta. 2013 May;1832(5):685-95. doi: 10.1016/j.bbadis.2013.02.003. Epub 2013 Feb 11.

Abstract

The hallmark of NAFLD is steatosis of unknown etiology. We tested the effect of a high-protein (HP)(2) diet on diet-induced steatosis in male C57BL/6 mice with and without pre-existing fatty liver. Mice were fed all combinations of semisynthetic low-fat (LF) or high-fat (HF) and low-protein (LP) or HP diets for 3weeks. To control for reduced energy intake by HF/HP-fed mice, a pair-fed HF/LP group was included. Reversibility of pre-existing steatosis was investigated by sequentially feeding HF/LP and HF/HP diets. HP-containing diets decreased hepatic lipids to ~40% of corresponding LP-containing diets, were more efficient in this respect than reducing energy intake to 80%, and reversed pre-existing diet-induced steatosis. Compared to LP-containing diets, mice fed HP-containing diets showed increased mitochondrial oxidative capacity (elevated Pgc1α, mAco, and Cpt1 mRNAs, complex-V protein, and decreased plasma free and short-chain acyl-carnitines, and [C0]/[C16+C18] carnitine ratio); increased gluconeogenesis and pyruvate cycling (increased PCK1 protein and fed plasma-glucose concentration without increased G6pase mRNA); reduced fatty-acid desaturation (decreased Scd1 expression and [C16:1n-7]/[C16:0] ratio) and increased long-chain PUFA elongation; a selective increase in plasma branched-chain amino acids; a decrease in cell stress (reduced phosphorylated eIF2α, and Fgf21 and Chop expression); and a trend toward less inflammation (lower Mcp1 and Cd11b expression and less phosphorylated NFκB).

Conclusion: HP diets prevent and reverse steatosis independently of fat and carbohydrate intake more efficiently than a 20% reduction in energy intake. The effect appears to result from fuel-generated, highly distributed small, synergistic increases in lipid and BCAA catabolism, and a decrease in cell stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids / blood
  • Animals
  • Blood Glucose / metabolism
  • Blotting, Western
  • Cholesterol / blood
  • Dietary Fats / administration & dosage
  • Dietary Fats / pharmacology
  • Dietary Proteins / administration & dosage
  • Dietary Proteins / pharmacology*
  • Fatty Acids, Nonesterified / blood
  • Fatty Liver / blood
  • Fatty Liver / genetics
  • Fatty Liver / prevention & control*
  • Fibroblast Growth Factors / blood
  • Fibroblast Growth Factors / genetics
  • Fibroblast Growth Factors / metabolism
  • Gene Expression / drug effects
  • Insulin / blood
  • Liver / drug effects*
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria / drug effects*
  • Mitochondria / genetics
  • Mitochondria / metabolism
  • NF-kappa B / metabolism
  • Non-alcoholic Fatty Liver Disease
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Phosphorylation / drug effects
  • Reverse Transcriptase Polymerase Chain Reaction
  • Ribosomal Protein S6 Kinases, 70-kDa / metabolism
  • Trans-Activators / genetics
  • Trans-Activators / metabolism
  • Transcription Factors
  • Triglycerides / blood
  • Triglycerides / metabolism
  • Weight Gain / drug effects

Substances

  • Amino Acids
  • Blood Glucose
  • Dietary Fats
  • Dietary Proteins
  • Fatty Acids, Nonesterified
  • Insulin
  • NF-kappa B
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Ppargc1a protein, mouse
  • Trans-Activators
  • Transcription Factors
  • Triglycerides
  • fibroblast growth factor 21
  • Fibroblast Growth Factors
  • Cholesterol
  • Ribosomal Protein S6 Kinases, 70-kDa